European Union´s Horizon 2020 – Lipum2021-03-15T12:44:19+01:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

1903, 2021

Lipum’s final report for Horizon 2020 has been approved

March 19th, 2021|

Press release: Umeå, 18 March 2021. Lipum's final report for the EU's Horizon 2020 framework program has been approved and the company will receive 496,000 EUR as final payment from the program. Horizon 2020, the EU's framework program for research and development, has granted Lipum a total of EUR 2.2 [...]

312, 2020


December 3rd, 2020|

In the magazine "Skelett och ledhälsa” our founders Professor Olle Hernell, Dr. Susanne Lindquist and Professor Lennart Lundberg were interviewed about our drug candidate SOL-116. SOL-116 is the antibody that we have developed for the treatment of chronic inflammatory diseases and we are now moving towards an IPO to secure [...]

2311, 2020


November 23rd, 2020|

At Biostock Life Science Summit last week our CEO Einar Pontén presented the recent progress in bringing our lead candidate SOL-116 towards clinical verification. He also briefly described Lipum’s strategy to pre-clinically explore a palette of chronic inflammatory conditions in parallel. Altogether it will constitute a solid [...]

1311, 2020

Digital Resi – Three day conference

November 13th, 2020|

Lipum will participate at Digital RESI (Redefining Early Stage Investments), a dedicated global partnering event. The challenge for the attendees will be the geographic time zone issues and that may require some flexibility. Fortunately, being virtual and being able to extend the conference from a one day physical to a [...]

1011, 2020

Biostock Life Science Summit

November 10th, 2020|

Our CEO Einar Pontén is preparing for BioStock Life Science Summit on 17 November at 12:30. He will present our unique approach to treat chronic inflammations and the progress with the lead candidate SOL-116. It has now been produced in 200L scale and is ready for toxicological studies that will [...]

610, 2020

Norrlandsfonden invests in lipum

October 6th, 2020|

Susanne Lindquist and Olle Hernell, two of Lipums founders. - Lipum is a very exciting company in drug development that also has a strong sustainability perspective, says Anna Hedström, Norrlandsfonden, in the press release published on MyNewsdesk. Read the full press release here » (in Swedish)

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€



Go to Top